Last reviewed · How we verify

NCT06970327

Totally Laparoscopic Distal Gastrectomy VS Pylorus-Preserving Gastrectomy for Early Gastric Cancer in the Middle Stomach

Completed Last updated 14 May 2025
What this trial tests

trial in Gastrectomy in 95 participants. Completed in 1 March 2025.

Timeline
1 January 2020
Primary endpoint
1 March 2025
1 March 2025

Quick facts

Lead sponsorChangzhi Medical College
StatusCompleted
Study typeOBSERVATIONAL
Enrollment95
Start date1 January 2020
Primary completion1 March 2025
Estimated completion1 March 2025
Sites1 location across China

Conditions studied

Sponsor

Changzhi Medical College

Who can join

Adults 18 to 85, any sex, with Gastrectomy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

With the development of laparoscopic technology, the surgical treatment of early gastric cancer (EGC) has shifted towards minimally invasive, precise, and function-preserving strategies. Totally laparoscopic distal gastrectomy (TLDG) and totally laparoscopic pylorus-preserving gastrectomy (TLPPG) are minimally invasive procedures. However, there is a lack of systematic evidence to directly compare their efficacies. This study focuses on two fully laparoscopic techniques, TLDG and TLPPG, to address two key objectives: (1) whether TLPPG can avoid the long-term functional sequelae of TLDG while ensuring oncological safety, including complications (delayed gastric emptying, reflux, and dumping syndrome), postoperative quality of life (assessed via the PGSAS-37 scale), and survival outcomes; and (2) the balance between complications and survival in function-preserving surgery. The findings aim to provide critical technical parameters for individualized surgical decision-making in EGC.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Gastrectomy

Currently open trials in the same condition.

Other Changzhi Medical College trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06970327.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing